Unlike JNK1 and JNK2 that are expressed throughout the body, JNK3 is primarily expressed in the brain; therefore, JNK3 has been considered a potential therapeutic target for neurodegenerative diseases [38]. Here, MAPK9 is linked to neurodegenerative disease.